经皮冠状动脉介入治疗对冠心病心力衰竭患者的临床疗效分析  

Clinical effect analysis of percutaneous coronary intervention on patients with coronary heart disease and heart failure

作　　者：王文侠 WANG Wen-xia(Cardiovascular Department,Xuzhou Mining Hospital,Xuzhou 221006,China)

机构地区：[1]徐州市矿山医院心血管内科,221006

出　　处：《中国实用医药》2024年第17期6-9,共4页China Practical Medicine

摘　　要：目的研究经皮冠状动脉介入治疗(PCI)对冠心病心力衰竭患者的临床疗效。方法选取106例冠心病心力衰竭患者,按照随机抽签法分为观察组(53例,采取PCI)和对照组(53例,采取常规治疗)。比较两组的临床疗效,炎症因子[C反应蛋白(CRP)、基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)]水平,心功能指标[左心室射血分数(LVEF)、左室后壁厚度(LVPW)和左心室短轴缩短率(LVFS)],心血管事件发生情况。结果观察组的治疗总有效率96.23%高于对照组的81.13%(P<0.05)。治疗前,两组CRP、MMP-9、IL-6水平比较无差异(P>0.05);治疗后,观察组CRP(4.58±1.19)mg/L、MMP-9(32.55±3.86)ng/L、IL-6(68.42±10.33)ng/L均低于对照组的(7.74±1.29)mg/L、(46.13±6.71)ng/L、(91.35±11.27)ng/L(P<0.05)。治疗前,两组LVEF、LVPW和LVFS比较无差异(P>0.05);治疗后,两组LVEF、LVPW和LVFS均优于治疗前,且观察组LVEF(58.71±3.66)%、LVPW(9.08±0.46)mm和LVFS(28.55±4.03)%均优于对照组的(44.17±4.08)%、(10.89±0.73)mm、(23.40±3.62)%(P<0.05)。观察组心肌梗死和脑卒中发生率分别为3.77%、1.89%,均低于对照组的15.09%、13.21%(P<0.05);两组心源性死亡、再次血运重建、全因死亡发生率比较无差异(P>0.05)。结论对冠心病心力衰竭患者采取PCI的效果确切,能够调节机体的炎症因子水平,并有效改善心功能,降低不良心血管事件的发生风险。Objective To study the clinical efficacy of percutaneous coronary intervention(PCI)on patients with coronary heart disease and heart failure.Methods A total of 106 patients with coronary heart disease and heart failure were divided into an observation group(53 cases,PCI)and a control group(53 cases,conventional treatment)according to random lottery method.Both groups were compared in terms of clinical efficacy,levels of inflammatory factors[C-reactive protein(CRP),matrix metalloproteinase-9(MMP-9),interleukin-6(IL-6)],cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular posterior wall thickness(LVPW),left ventricular short axis shortening rate(LVFS)]and cardiovascular events.Results The total effective rate of 96.23%in the observation group was higher than 81.13%in the control group(P<0.05).Before treatment,there were no differences in CRP,MMP-9 and IL-6 levels between the two groups(P>0.05).After treatment,the observation group had CRP of(4.58±1.19)mg/L,MMP-9 of(32.55±3.86)ng/L and IL-6 of(68.42±10.33)ng/L,which were lower than(7.74±1.29)mg/L,(46.13±6.71)ng/L and(91.35±11.27)ng/L in the control group(P<0.05).Before treatment,there were no differences in LVEF,LVPW and LVFS between the two groups(P>0.05).After treatment,LVEF,LVPW and LVFS in both groups were better than those before treatment;the observation group had LVEF of(58.71±3.66)%,LVPW of(9.08±0.46)mm and LVFS of(28.55±4.03)%,which were better than(44.17±4.08)%,(10.89±0.73)mm and(23.40±3.62)%in the control group(P<0.05).The incidence of myocardial infarction and stroke in the observation group were 3.77%and 1.89%,which were lower than 15.09%and 13.21%in the control group(P<0.05).There was no difference in the incidence of cardiac death,revascularization and all-cause death between the two groups(P>0.05).Conclusion PCI is effective in patients with coronary heart disease and heart failure,which can regulate the level of inflammatory factors,effectively improve cardiac function,and reduce the risk of adverse cardi

关 键 词：经皮冠状动脉介入治疗 冠心病 心力衰竭 心功能 

分 类 号：R541.4[医药卫生—心血管疾病] R541.6[医药卫生—内科学]